Exhibit 10.53
Amendment No. 2
To Collaboration Agreement
This Amendment No. 2
to the Collaboration Agreement (“Amendment
No. 2”) is made and entered into on December 31 ,
2004 by and between Exelixis, Inc ., a Delaware
corporation, located at 170 Harbor Way, P.O. Box 511, South San
Francisco, California 94083-0511 (“Exelixis”), and
Cytokinetics,
Inc., a Delaware corporation, located at 280 East Grand
Avenue, South San Francisco, California 94080
(“Cytokinetics”). Each of the above parties is
individually referred herein to as a “Party” or
collectively as the “Parties”.
Whereas ,
Exelixis and Cytokinetics entered into the Collaboration Agreement
on December 28, 2001, as previously amended by that certain
First Letter Amendment effective March 31, 2003 (the
“Agreement”); and
Whereas
, the Agreement
provides for Exelixis to supply compounds to Cytokinetics in order
for the Parties to conduct on a collaborative basis a research
program with the principal goal of producing a high throughput
screen library (“Research Program”); and
Whereas ,
Exelixis and Cytokinetics mutually desire to terminate the
Agreement w
